TMA can be classified according to its pathophysiology into: ADAMTS-13 deficiency-mediated, as in TTP and thrombocytopenia-associated multiple organ failure (TAMOF); complement-mediated, as in atypical HUS; and Shiga toxin-mediated.2 This evidence concerns the gene ADAMTS13 and atypical hemolytic-uremic syndrome.